
OCT Bests Angiography Guidance for Improving PCI Outcomes
Gregg Stone, MD
'We found that in those calcified lesions there was a marked benefit of optical coherence tomography [OCT] guidance compared with angiography guidance in improving long-term outcomes, specifically in reducing the 2-year rate of target vessel failure and serious adverse cardiovascular events, as well as stent thrombosis,' study leader Gregg Stone, MD, director of academic affairs for Mount Sinai Heart Health System in New York City, told Medscape Medical News.
Results of the analysis were published in the European Heart Journal .
Substudy Results
The study included 2114 patients from the ILUMIEN IV clinical trial, which compared OCT- and angiography-guided percutaneous coronary intervention (PCI). The participants in the substudy had a single treated calcified lesion in a major epicardial vessel. On angiographic guidance, 1082 patients (51.2%) had a moderately or severely calcified lesion and 1032 (48.8%) had no or mild calcification.
Using angiographic guidance alone, the rate of target vessel failure at 2 years in the moderately or severely calcified lesions was 93% greater than that in the lesions with no or mild calcification (9.7% vs 5.2%).
However, with OCT guidance, the 2-year rates of failure were similar in both groups, 6.8% in the moderately and severely calcified lesions and 7.7% in the no or mildly calcified lesions.
With OCT guidance, the 2-year failure rates were 38% lower compared with angiography guidance in the patients with moderately and severely calcified lesions: 6.8% vs 9.7%. The differences in the patients with no or mild calcification were not statistically significant, the substudy found: 7.7% with OCT guidance and 5.2% with angiographic guidance ( P = .01).
The three major predictors of vessel failure after PCI, Stone said, are minimal stent area and a major dissection or untreated disease at the edge of the stent. 'The real advantage of optical coherence tomography is that it provides a much more accurate picture than angiography in determining the minimal stent area or in detecting edge-related dissections or significant untreated disease,' he said.
The 2024 European Society of Cardiology guidelines recommend intravascular imaging as a Class IA indication for anatomically complex lesions, Stone noted; but those guidelines do not specifically call out calcified lesions. 'That's the major gap this study fills,' he said.
The American College of Cardiology, in conjunction with the American Heart Association and the Society for Cardiovascular Angiography and Intervention, this year issued a Class 1A recommendation for intracoronary imaging, including OCT, during stenting of the left main artery or for other complex lesions.
'Directly Relatable to the Clinic'
While OCT operators need a high level of skill to perform the imaging and interpret the results, the substudy findings are 'quite generalizable to all settings,' Stone said.
'These findings are directly translatable to the clinic, but there's always more fine tuning that can be performed,' he added. That refining would include clarification of the characteristics of calcified plaque on OCT that are at highest risk for target vessel failure, and possibly the need for an advanced strategy of lesion preparation, using either lithotripsy, atherectomy or cutting or scoring balloons, he said.
Several calcium scoring classifications for OCT have been proposed, but none has been clinically validated. 'That would be a rich area for future research,' Stone said.
Clinical Context
Yader Sandoval, MD
The new data underscore the value of intravascular imaging, and add to the data supporting OCT specifically, for characterizing plaque in percutaneous coronary intervention, Yader Sandoval, MD, an interventional cardiologist at the Minneapolis Heart Institute at Abbott Northwestern Hospital and cochair for the Center for Coronary Artery Disease at the Minneapolis Heart Institute Foundation, Minneapolis, told Medscape Medical News .
'This analysis of ILUMIEN IV complements and further adds that this is the right direction that intravascular imaging not only provides superior technical results but it improves outcomes for these patients,' Sandoval said.
The substudy clears up a finding from the original ILUMIEN IV study that, while OCT guidance resulted in a larger minimal stent area than angiography guidance, it did not necessarily reduce target vessel failure at 2 years.
A strength of the ILUMIEN IV trial was the 'meticulous core laboratory data analysis' used, along with its global scope, he said.
The substudy, also reported using OCT guidance, took about 16 minutes longer per procedure than angiography (67.7 minutes vs 51.5 minutes) and required longer fluoroscopy duration and greater total radiation dose, Sandoval said, which could raise questions about the practicality of OCT for this indication.
'The main message is, you are better characterizing calcium and therefore better preparing the lesion and providing a better technical result, better area, and better results for the patient,' he said. 'That comes with the investment that the procedure is little more complex, and you have to do a better job of preparing the lesion. And to me these data elegantly show that.'
Abbott Vascular provided funding for this study. Stone reported receiving speaking fees from Abbott. Sandoval reported serving as a consultant, advisory board member, and a speaker for Abbott.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
an hour ago
- CBS News
President Trump's "big, beautiful bill" threatens Medicaid access for millions in Florida, advocates warn
Millions of Floridians could lose access to life-saving Medicaid coverage under a new legislation that slashes billions of dollars in federal funding, health advocates warn. The Florida Health Justice Project estimates the legislation will cut about $4 billion annually in federal Medicaid support to the state, impacting at least one million current recipients. While it's unclear exactly who will lose coverage, advocates say the most vulnerable populations — including elderly residents who rely on Medicaid to help pay for Medicare premiums and legal immigrants with temporary status — will be among the first affected. "There's really just one step away from sheer panic," said Lynn Hearn of the Florida Health Justice Project. "If you have a person with a severe disability, they are relying upon the services of Medicaid literally to stay alive." In Florida, roughly four million low-income individuals or people with disabilities depend on Medicaid, the government-funded health insurance program. Florida residents with disabilities fear tighter Medicaid restrictions Paolo Linares, a Liberty City resident, is among them. Diagnosed with autism and ADHD, she lives at home but was hoping to gain independence by moving out. She said the new restrictions could make Medicaid inaccessible when she needs it most. "This type of paperwork may make it harder in the case that I may need it," Linares said. "If you're going to put more stricter things on this, what are you going to do to help these people?" Clinics may close as Medicaid cuts ripple through Florida's health system The ripple effects could reach beyond Medicaid recipients. Hearn said as fewer people are able to seek care, medical providers may not be able to stay in business — affecting access for even those who remain insured. "When there aren't as many people who are insured and able to go to the doctor and get services, then those service providers aren't able to maintain their business," she said. "And then they shut down." Among those expected to lose coverage are refugees, asylum seekers, parolees, and others from countries like Afghanistan and Syria who are in the U.S. legally but lack permanent resident status. "These are people who have been able to get coverage for their families, but that will end," Hearn said. She added that the next state budget cycle will likely force Florida to make tough choices about what Medicaid benefits to continue funding. For now, the Florida Health Justice Project said it will focus efforts on lobbying state lawmakers to secure alternative funding for the program.


CBS News
an hour ago
- CBS News
Deadly opioid carfentanil reemerges in Michigan, linked to 11 deaths in 2025
Michigan health officials say the state is seeing a reemergence of the potentially deadly opioid carfentanil. Carfentanil is a synthetic opioid, typically used by veterinarians to tranquilize large animals, like elephants, and is not approved for use in humans. State health officials say that so far this year, 11 deaths involving carfentanil have been identified. None of those individuals tested positive for carfentanil alone. Ten of those who died also tested for cocaine, and fentanyl was found in eight of those deaths. The deaths occurred in Ingham, Livingston, Eaton, Genesee, Oakland and Wayne counties. The synthetic drug is a small, white, powdery substance that looks like cocaine or heroin, but officials with the Drug Enforcement Administration say that using even a small amount could kill. "Imagine like a speck of baby powder; that's how much could be a lethal dosage of carfentanil," said Brian McNeal, public information officer with the DEA's Detroit division. "It is a Schedule II drug, meaning it does have medical use, but it is not approved for human use, and it has found its way into the illicit drug supply." Carfentanil is 100 times more potent than fentanyl and about 10,000 times more potent than morphine, according to the Michigan Department of Health and Human Services. "Carfentanil is an extremely potent and deadly drug," said Dr. Natasha Bagdasarian, Chief Medical Executive for the State of Michigan. "We're urging people who use unregulated drugs – and their loved ones – to carry naloxone, an easy to administer nasal spray that can reverse opioid overdoses and save lives. Awareness and quick action can help save lives." The DEA says some users mix carfentanil with other drugs like OxyContin or Xanax. "Whether it's heroin, marijuana, or cocaine, it follows the same routes up from our southwest border into distribution hub, like any other business, and then into smaller communities and neighborhood, but the precursor chemicals mainly come from Asia, from China, India into Mexico, where drug cartels are putting these chemicals into the illicit drug supply," McNeal said. Carfentanil was previously seen in the state in 2016 and 2017, with the drug contributing to 107 deaths in 2016 and 111 deaths in 2017. Deaths associated with the drug fell in recent years, dropping to a handful a year in 2018, 2019 and 2020, and then to zero in 2021 and 2022. Health officials say the drug can rapidly cause central nervous system depression, which can lead to quick death, and that because an increasing number of overdose deaths associated with carfentanil also include cocaine, methamphetamine and other stimulants, users may not know those drugs contain carfentanil. Treating a carfentanil overdose can also be extremely difficult, and officials say reversing an overdose may require several doses of naloxone.
Yahoo
an hour ago
- Yahoo
US Probiotics Market Poised for Strong Growth Amid Surging Demand for Digestive Health Solutions
Delray Beach, FL, July 02, 2025 (GLOBE NEWSWIRE) -- A new research report, 'US Probiotics Market by Ingredient (Bacteria and Yeast), Product Type (Functional Food & Beverages, Dietary Supplements, and Feed), End User (Human and Animal), Distribution Channel, and Region', highlights robust growth in the US probiotics market. The market is booming as consumers increasingly recognize the vital connection between gut health and overall well-being. Get PDF Brochure Now: Digestive Health Awareness Fuels Market Boom A wave of digestive health awareness is sweeping the nation, driven by interest in preventive care, natural wellness solutions, and healthy aging. Americans are turning to probiotics from yogurts and supplements to kombucha and snacks — to support gastrointestinal health and manage conditions like IBS and IBD. Regional Hotspots: California, New York, Texas Lead the Probiotic Revolution Regional trends show California, New York, and Texas at the forefront of probiotic consumption, fueled by their diverse, health-focused populations and dynamic retail and Innovative Products Meet Growing Demand From functional foods and drinks to skincare and beauty applications, the US probiotics industry offers consumers an ever‑expanding selection of probiotic‑enriched products designed to fit modern lifestyles. Today, probiotics are available across a wide range of categories, making it easier than ever for people to integrate gut‑friendly benefits into their daily routine. These products include: Yogurt and Kefir: The traditional staples of probiotic nutrition. Kombucha and Functional Beverages: Refreshing drinks packed with gut‑friendly bacteria. Dietary Supplements: Capsules, powders, and gummies with targeted probiotic strains. Snacks and Nutrition Bars: Convenient options for on‑the‑go probiotic support. Skincare and Beauty Products: New formulations that harness the benefits of probiotics for skin health and microbiome balance. Personalized Nutrition Solutions: Tailored probiotic supplements based on individual microbiome profiles. Explore Growth Opportunities in the Booming US Probiotics Market Strong Endorsement from Research and Surveys The 2022 IFIC Food and Health Survey found that around one-third of Americans try to consume probiotics, with nearly 60% doing so daily. This reflects shifting preferences toward natural, functional ingredients amid rising rates of obesity and micronutrient deficiencies. Industry Leaders Drive Awareness and Innovation Powerhouse brands like ADM (US), International Flavors & Fragrances Inc. (US), BioGaia (Sweden), Lifeway Foods, Inc. (US), Winclove Probiotics (US), and Lallemand (Canada) are at the forefront, investing in consumer education, marketing, and product development to meet growing demand. The Road Ahead for the US Probiotics Market As probiotics go mainstream, the US market is poised for continued expansion, driven by advances in microbiome research, personalized nutrition, and cross-industry collaborations. As Americans continue to prioritize their well‑being and seek natural alternatives for health maintenance, probiotics are poised for long‑term growth. The trend goes beyond consumer preference; it signifies a shift towards a more mindful approach to nutrition and a holistic understanding of how gut health influences immunity, mood, and overall quality of life. With advances in microbiome science and the growing role of personalized nutrition, the US probiotics market is expected to evolve even further — opening new opportunities for innovation and making probiotic-rich products an integral part of daily life. Key Questions Addressed by US Probiotics Market Report What is driving the growth of the probiotics market in the US? What are the most popular probiotic products in the US? Which US states have the highest demand for probiotic products? What health conditions are probiotics most used for in the US? Are probiotics gaining popularity beyond supplements? Who are the leading brands in the US probiotics market? What is the future outlook for the probiotics market in the US? What are the key product types considered in the study for Probiotics, and which segments within Asia Pacific's Functional Food & Beverages product type are projected to experience promising growth? Is there customizable information available specific to the North America Feed market within the Probiotics study, and if so, what details are provided? Could you highlight the opportunities identified in the study that are expected to fuel the future growth of the Probiotics market? Among the regions studied, which one is anticipated to exhibit the CAGR for the Probiotics market? What is the market trend for probiotics? How big is the probiotics market? Why are probiotics so popular now? What is the probiotic industry? What is the market outlook for probiotics? What will happen with probiotics in future? Who is the target market for probiotics? Does the FDA regulate probiotics? Are probiotics a trend? What is the probiotic market forecast? What is the price prediction for Flora growth? What is the trend in probiotics drinks? What are next generation probiotics? What are next generation probiotics FDA? CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@ Visit Our Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data